Prometheus Biosciences Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
+2.48 (+13.19 %)
(As of 04/13/2021 12:00 AM ET)
Today's Range
Now: $21.28
50-Day Range N/A
52-Week Range
Now: $21.28
Volume211,607 shs
Average Volume3.04 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
Prometheus Biosciences logo

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:RXDX
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.97 out of 5 stars

Medical Sector

71st out of 2,019 stocks

Biotechnology Industry

6th out of 145 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Receive RXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for RXDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Prometheus Biosciences (NASDAQ:RXDX) Frequently Asked Questions

Is Prometheus Biosciences a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Prometheus Biosciences stock.
View analyst ratings for Prometheus Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Prometheus Biosciences?

Wall Street analysts have given Prometheus Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Prometheus Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Prometheus Biosciences' earnings last quarter?

Prometheus Biosciences, Inc. (NASDAQ:RXDX) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.03.
View Prometheus Biosciences' earnings history

What price target have analysts set for RXDX?

4 Wall Street analysts have issued 1 year target prices for Prometheus Biosciences' stock. Their forecasts range from $25.00 to $40.00. On average, they expect Prometheus Biosciences' stock price to reach $32.25 in the next year. This suggests a possible upside of 51.6% from the stock's current price.
View analysts' price targets for Prometheus Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Prometheus Biosciences' key executives?

Prometheus Biosciences' management team includes the following people:
  • Mr. Mark C. McKenna, Pres, CEO & Director (Age 41, Pay $1.51M)
  • Dr. Keith W. Marshall M.B.A., MBA, Ph.D., CFO & Treasurer (Age 53, Pay $458.22k)
  • Mr. Mark Stenhouse, Chief Operating Officer (Age 54)
  • Dr. Allison Luo M.D., Chief Medical Officer (Age 48, Pay $586.13k)
  • Mr. Gerald T. Proehl, Advisor
  • Dr. Olivier Laurent Ph.D., Chief Technology Officer (Age 49)
  • Dr. Laurens Kruidenier Ph.D., Chief Scientific Officer (Age 51)
  • Ms. Noel Kurdi, VP of Investor Relations & Communications
  • Mr. Timothy K. Andrews Esq., Gen. Counsel & Sec. (Age 42)
  • Dr. Thierry Dervieux DABCC, Pharm.d., Ph.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director (Age 53)

Who are some of Prometheus Biosciences' key competitors?

What other stocks do shareholders of Prometheus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), SELLAS Life Sciences Group (SLS), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TransEnterix (TRXC) and TherapeuticsMD (TXMD).

When did Prometheus Biosciences IPO?

(RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is Prometheus Biosciences' stock symbol?

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

When does Prometheus Biosciences' quiet period expire?

Prometheus Biosciences' quiet period expires on Wednesday, April 21st. Prometheus Biosciences had issued 10,000,000 shares in its IPO on March 12th. The total size of the offering was $190,000,000 based on an initial share price of $19.00. During Prometheus Biosciences' quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

What is Prometheus Biosciences' stock price today?

One share of RXDX stock can currently be purchased for approximately $21.28.

How many employees does Prometheus Biosciences have?

Prometheus Biosciences employs 24 workers across the globe.

What is Prometheus Biosciences' official website?

The official website for Prometheus Biosciences is

Where are Prometheus Biosciences' headquarters?

Prometheus Biosciences is headquartered at 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States.

How can I contact Prometheus Biosciences?

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company can be reached via phone at +1-858-2555959.

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.